The recent deaths in Sarepta’s gene therapy trials have reignited debates reminiscent of the Jesse Gelsinger incident about safety oversight in gene therapy. Industry experts and patient advocates emphasize the need for collaborative evaluation of risks to prevent avoidable tragedies. Sarepta’s transparency and FDA’s demands highlight tensions around patient safety, regulatory responses, and the future direction of AAV-based viral vector therapies for muscular dystrophies.